JP2016520617A5 - - Google Patents

Download PDF

Info

Publication number
JP2016520617A5
JP2016520617A5 JP2016517041A JP2016517041A JP2016520617A5 JP 2016520617 A5 JP2016520617 A5 JP 2016520617A5 JP 2016517041 A JP2016517041 A JP 2016517041A JP 2016517041 A JP2016517041 A JP 2016517041A JP 2016520617 A5 JP2016520617 A5 JP 2016520617A5
Authority
JP
Japan
Prior art keywords
substituted
unsubstituted
protecting group
heterocyclyl
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016517041A
Other languages
English (en)
Japanese (ja)
Other versions
JP6557654B2 (ja
JP2016520617A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/040231 external-priority patent/WO2014197313A2/en
Publication of JP2016520617A publication Critical patent/JP2016520617A/ja
Publication of JP2016520617A5 publication Critical patent/JP2016520617A5/ja
Application granted granted Critical
Publication of JP6557654B2 publication Critical patent/JP6557654B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016517041A 2013-05-30 2014-05-30 新規の化合物及びその使用 Expired - Fee Related JP6557654B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361829117P 2013-05-30 2013-05-30
US61/829,117 2013-05-30
US201361898719P 2013-11-01 2013-11-01
US61/898,719 2013-11-01
PCT/US2014/040231 WO2014197313A2 (en) 2013-05-30 2014-05-30 Novel compounds and uses thereof

Publications (3)

Publication Number Publication Date
JP2016520617A JP2016520617A (ja) 2016-07-14
JP2016520617A5 true JP2016520617A5 (https=) 2017-07-20
JP6557654B2 JP6557654B2 (ja) 2019-08-07

Family

ID=52008726

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016517041A Expired - Fee Related JP6557654B2 (ja) 2013-05-30 2014-05-30 新規の化合物及びその使用

Country Status (7)

Country Link
US (5) US9988386B2 (https=)
EP (1) EP3003314B1 (https=)
JP (1) JP6557654B2 (https=)
AU (1) AU2014275198B2 (https=)
CA (1) CA2913417A1 (https=)
HK (1) HK1223307A1 (https=)
WO (1) WO2014197313A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2913417A1 (en) * 2013-05-30 2014-12-11 Kala Pharmaceuticals, Inc. Substituted n-(5-(2-aminoimidaz0[1,2-b]pyridazin-6-yloxy) derivatives a nd pharmaceutical compositions thereof useful for the treatment of diseases associated with abnormal angiogenesis and/or aberrant signaling of a growth factor
CN113122269B (zh) * 2014-09-30 2024-05-28 光学转变公司 紫外光吸收剂
WO2016086026A1 (en) * 2014-11-26 2016-06-02 Kala Pharmaceuticals, Inc. Crystalline forms of a therapeutic compound and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002232439A1 (en) * 2000-11-29 2002-06-11 Glaxo Group Limited Benzimidazole derivatives useful as tie-2 and/or vegfr-2 inhibitors
US7531553B2 (en) * 2003-03-21 2009-05-12 Amgen Inc. Heterocyclic compounds and methods of use
US20100029619A1 (en) * 2006-08-04 2010-02-04 Takeda Pharmaceutical Company Limted Fused heterocyclic compound
PE20080538A1 (es) 2006-08-04 2008-06-18 Takeda Pharmaceutical Derivado heterociclico fusionado y su uso
AR067326A1 (es) * 2007-05-11 2009-10-07 Novartis Ag Imidazopiridinas y pirrolo -pirimidinas sustituidas como inhibidores de cinasa de lipido
US8344135B2 (en) * 2007-08-29 2013-01-01 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
JPWO2009096435A1 (ja) * 2008-01-29 2011-05-26 武田薬品工業株式会社 縮合複素環誘導体およびその用途
WO2010032880A2 (en) 2008-09-19 2010-03-25 Takeda Pharmaceutical Company Limited Prophylactic/therapeutic agent for cancer
JP2010126530A (ja) * 2008-12-01 2010-06-10 Takeda Chem Ind Ltd 縮合複素環誘導体およびその用途
NZ742005A (en) 2012-05-03 2019-04-26 Kala Pharmaceuticals Inc Pharmaceutical nanoparticles showing improved mucosal transport
KR102310775B1 (ko) 2012-05-03 2021-10-07 칼라 파마슈티컬스, 인크. 개선된 점막 수송을 나타내는 제약 나노입자
CA2913417A1 (en) * 2013-05-30 2014-12-11 Kala Pharmaceuticals, Inc. Substituted n-(5-(2-aminoimidaz0[1,2-b]pyridazin-6-yloxy) derivatives a nd pharmaceutical compositions thereof useful for the treatment of diseases associated with abnormal angiogenesis and/or aberrant signaling of a growth factor

Similar Documents

Publication Publication Date Title
JP2016517417A5 (https=)
JP2016505637A5 (https=)
JP2019514956A5 (https=)
JP2017537940A5 (https=)
JP2016515560A5 (https=)
JP2016513130A5 (https=)
JP2021521178A5 (https=)
RU2016137678A (ru) Соединения с эфирными группами для лечения опосредованных комплементом нарушений
WO2017035355A1 (en) Ether compounds for treatment of medical disorders
JP2013502431A5 (https=)
JP2016503797A5 (https=)
JP2013515074A5 (https=)
JP2018502891A5 (https=)
JP2014511892A5 (https=)
RU2016115082A (ru) Замещенные аминопиримидиновые соединения и способы их использования
JP2016531113A5 (https=)
JP2017518360A5 (https=)
JP2014506582A5 (https=)
RU2016151420A (ru) Новое терапевтическое применение производных бензилиденгуанидина для лечения протеинопатий
JP2013533883A5 (https=)
JP2021504317A5 (https=)
JP2013532652A5 (https=)
JP2019507111A5 (https=)
JP2016528245A5 (https=)
JP2018527295A5 (https=)